USPTO Patent Grant: RAS Oncoprotein Inhibitors

The United States Patent and Trademark Office (USPTO) has issued patent US12582660B2, covering compounds for treating diseases associated with RAS oncoprotein activity, including cancer. The patent, assigned to the University of Louisville Research Foundation, Inc., details specific compounds of Formula (I) and their therapeutic applications.

This patent grant signifies a new intellectual property right for the assignee. While not a regulatory mandate for other entities, it establishes exclusive rights for the patent holder in the US for the claimed inventions. Companies involved in oncology drug development, particularly those targeting RAS pathways, should be aware of this granted patent to avoid potential infringement and to understand the competitive landscape.